Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing a rethink
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
In Depth: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad
Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing buyers and sellers to rethink…
Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic…
China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.
Chinese drug makers are increasingly relying on overseas licensing deals to reach global markets amid growing geopolitical…
Executives seek “skin in the game” despite signs of a stock market cooldown.
As large biopharma companies have increasingly turned to China for novel biotech innovation, political calls in the U.S. to block…
